Apogee's Positive Phase 1b Results Suggest Long-Acting Asthma and Atopic Dermatitis Therapy Potential
Interim Study Results Highlight Durable Effect and Favorable Safety Profile
Apogee Therapeutics (NASDAQ: APGE) has released interim data from its Phase 1b trial of zumilokibart (APG777), a novel extended half-life anti-IL-13 antibody, in adults with mild-to-moderate asthma and Type 2 inflammation. The data, announced ahead of a scheduled conference call, provides key clinical signals supporting further development of zumilokibart, which could play a foundational role in future asthma and dermatology treatments.
FeNO Suppression Lasts Beyond 16 Weeks After a Single Dose
In the double-blind, placebo-controlled trial, 19 patients with elevated baseline FeNO (=25 ppb) received a single 720 mg dose of zumilokibart or placebo. The results included:
- Maximum absolute mean FeNO reduction of 45 ppb—representing a 60% decrease from baseline, observed after a single dose.
- Durable FeNO suppression sustained through 16 weeks for all participants studied.
- Continued FeNO reduction through 32 weeks in patients with extended follow-up, underscoring the potential for less frequent dosing at three- or six-month intervals.
| Endpoint | Key Outcome |
|---|---|
| Absolute Mean FeNO Reduction | 45 ppb (60% decrease) |
| Duration of Suppression | 16 weeks (all patients), 32 weeks (subset) |
| Single Dose | 720 mg zumilokibart |
Safety and Tolerability Comparable to Placebo
Zumilokibart was well-tolerated, with no Grade 3 or higher adverse events and no serious adverse events reported. The only treatment-emergent adverse event (TEAE) seen in more than one participant was GERD (2 patients). Importantly, there were no observed cases of conjunctivitis, injection site reactions, or anti-drug antibodies, supporting zumilokibart's safety in this early trial.
Pipeline-in-a-Product: Expanding Into Multiple Indications
Beyond its promise in asthma, zumilokibart is advancing in a range of inflammatory and immunology (I&I) indications. For atopic dermatitis (AD), major clinical milestones are anticipated in 2026:
- APEX Phase 2 Part A (52-week) data expected in Q1 2026, targeting a best-in-class 3- or 6-month dosing profile.
- APEX Phase 2 Part B (16-week) induction results due Q2 2026, after enrolling 347 patients—exceeding initial recruitment targets.
- Initiation of a Phase 3 trial is planned for the second half of 2026, aiming for potential market launch in 2029.
- APG279, a fixed-dose combination targeting IL-13 and OX40L, is being evaluated head-to-head versus Dupixent with readout projected for the latter half of 2026.
| Trial | Expected Readout | Key Details |
|---|---|---|
| APEX Phase 2 Part A (AD) | Q1 2026 | 52-week maintenance; dosing every 3 or 6 months |
| APEX Phase 2 Part B (AD) | Q2 2026 | 347 patients enrolled |
| APG279 Head-to-Head vs. Dupixent | 2H 2026 | 80 patients (upsized due to strong demand) |
Strong Cash Position Supports Multi-Year Pipeline Progress
As of September 30, 2025, Apogee reported $913 million in total cash—projected to fund operations into the second half of 2028. This robust financial runway positions the company to advance zumilokibart and its pipeline, aiming for multiple clinical data catalysts and a potentially transformative few years ahead.
What to Watch Next: Key Clinical and Market Milestones
Apogee is forecasting a phase of dense clinical newsflow in 2026, with pivotal readouts in both asthma and atopic dermatitis. With fewer dosing requirements and a safety profile that may compare favorably to existing options, zumilokibart could redefine patient and physician expectations if larger trials confirm these early signals. Whether the therapy's promise translates into broader clinical success and regulatory approval remains a focus for 2026 and beyond.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI